Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao highlight gene therapy as a future treatment of neovascular AMD and DME and how it will significantly reduce the burden on patients.

Optical coherence tomography angiography (OCTA) was performed in all participants; the choroidal and retinal changes were examined and recorded. A new study 1 from Turkey reported that during the ...

The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...

During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy. As imaging modalities improve, so do ...

A program from National Health Service (NHS) England will bring optical coherence tomography (OCT) scans “closer to home” for thousands of patients. As part of an effort to improve outcomes for ...

Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat ...

Recapping a recent conversation led by Dilsher S. Dhoot, MD. In May 2025, Dilsher S. Dhoot, MD, moderated a Case-Based Roundtable® that brought together practicing retina specialists and residents ...

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...

The trial evaluated nesvategrast (OTT166 5%) eye drops in patients with diabetic retinopathy. OcuTerra announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) ...

Kriya Therapeutics presented preclinical data on its gene therapy candidate for the treatment of geographic atrophy. Kriya Therapeutics recently announced preclinical data on its gene therapy ...

Lexitas Pharma Services' CMO discusses groundbreaking ophthalmology conference, emphasizing innovative clinical trials, emerging treatments for eye diseases, and the potential for transformative ...

Results were published from the phase 3 QUASAR trial and the extension study of the phase 3 PULSAR trial. Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its ...